Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Gabapentin 150mg/5ml oral liquid
0408010G0AAANAN
|
Gabapentin | Gabapentin | Central Nervous System | No data available |
|
Gabapentin 450mg/5ml oral liquid
0408010G0AAARAR
|
Gabapentin | Gabapentin | Central Nervous System | No data available |
|
Gabapentin 600mg tablets and Gabapentin 300mg capsules
0408010G0AAAXAX
|
Gabapentin | Gabapentin | Central Nervous System | No data available |
|
Gabapentin 600mg/5ml oral liquid
0408010G0AABBBB
|
Gabapentin | Gabapentin | Central Nervous System | No data available |
|
Gabapentin 800mg/5ml oral liquid
0408010G0AABCBC
|
Gabapentin | Gabapentin | Central Nervous System | No data available |
|
Gabup 0.4mg sublingual tablets
0410030A0BEAFAC
|
Gabup | Buprenorphine hydrochloride | Central Nervous System | No data available |
|
Gabup 1mg sublingual tablets
0410030A0BEACAI
|
Gabup | Buprenorphine hydrochloride | Central Nervous System | No data available |
|
Gabup 2mg sublingual tablets
0410030A0BEAAAD
|
Gabup | Buprenorphine hydrochloride | Central Nervous System | No data available |
|
Gabup 4mg sublingual tablets
0410030A0BEAEAK
|
Gabup | Buprenorphine hydrochloride | Central Nervous System | No data available |
|
Gabup 6mg sublingual tablets
0410030A0BEADAJ
|
Gabup | Buprenorphine hydrochloride | Central Nervous System | No data available |
|
Gabup 8mg sublingual tablets
0410030A0BEABAE
|
Gabup | Buprenorphine hydrochloride | Central Nervous System | No data available |
|
Galake 10mg/500mg tablets
0407010N0BCAAAA
|
Galake | Co-dydramol (Dihydrocodeine/paracetamol) | Central Nervous System | No data available |
|
Galantamine 4mg tablets
0411000F0AAAAAA
|
Galantamine | Galantamine | Central Nervous System | No data available |
|
Galpamol for Children 120mg/5ml oral suspension
0407010H0CFACAW
|
Galpamol | Paracetamol | Central Nervous System | No data available |
|
Galpamol for Children 120mg/5ml susp 5ml sachets sugar free
0407010H0CFAAAJ
|
Galpamol | Paracetamol | Central Nervous System | No data available |
|
Galpharm All-In-One Cold & Flu Liquid
0407010X0CPAFBJ
|
Galpharm (Paracetamol combined) | Paracetamol combined preparations | Central Nervous System | No data available |
|
Galpharm Children's Paracetamol 120mg/5ml oral suspension
0407010H0CPACAW
|
Galpharm (Paracetamol) | Paracetamol | Central Nervous System | No data available |
|
Galpharm Flu Strength All in One oral solution
0407010X0CPAABJ
|
Galpharm (Paracetamol combined) | Paracetamol combined preparations | Central Nervous System | No data available |
|
Galpharm Flu-Max All-In-One Chesty Cough & Cold oral pdr
0407010X0CPAEA0
|
Galpharm (Paracetamol combined) | Paracetamol combined preparations | Central Nervous System | No data available |
|
Galpharm Flu-Max All-In-One Chesty Cough & Cold tablets
0407010X0CPADBI
|
Galpharm (Paracetamol combined) | Paracetamol combined preparations | Central Nervous System | No data available |
|
Galpharm Max Strength Cold & Flu capsules
0407010X0CPACA0
|
Galpharm (Paracetamol combined) | Paracetamol combined preparations | Central Nervous System | No data available |
|
Galpharm Max Strength Cold & Flu Lemon oral powder sachets
0407010ABBGACAB
|
Galpharm (Paracetamol/phenylephrine hydrochloride) | Paracetamol and phenylephrine hydrochloride | Central Nervous System | No data available |
|
Galpharm Nicotine Replace 2mg lozenges
0410020B0BMAAAY
|
Galpharm nicotine | Nicotine | Central Nervous System | No data available |
|
Galpharm Nicotine Replace 2mg medicated chewing gum
0410020B0BMACBA
|
Galpharm nicotine | Nicotine | Central Nervous System | No data available |
|
Galpharm Nicotine Replace 4mg lozenges
0410020B0BMABAZ
|
Galpharm nicotine | Nicotine | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.